ArticleCancer2020

When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.

Ryan D CassadayPubMed ↗Publisher ↗

No numbers read from the abstract.